Bae et al. demonstrated mechanisms whereby citarinostat in a dose- and time-dependent fashion augments immune response and mediates anti-MM activity both by decreasing CD138+ tumor cells and tumor-promoting immune cells and their expression of immune checkpoints, as well as by promoting the activation of antigen specific CD8+ T cells [168]. This evidence concerns the gene SDC1 and neoplasm.